A team headed by the Medical University of Vienna examined cancer prevalence and screening/prevention awareness among people who are experiencing homelessness in four European countries. The team proposed approaches for the development of a prevention program using the results. The study was published in eClinicalMedicine.
Researchers from the Keck School of Medicine of USC discovered that when cells are under stress, a key protein can travel to the nucleus and reprogram cells to migrate and become more invasive.
A novel blood testing technology being developed by researchers at the Johns Hopkins Kimmel Cancer Center that combines genome-wide sequencing of single molecules of DNA shed from tumors and machine learning may allow earlier detection of lung and other cancers.
A multi-institution study found that deletions of a certain tumor-suppressor gene in diffuse gliomas—the most common primary brain tumors—display distinct patterns, signify a poor prognosis in patients, and should be included in models predicting the clinical behavior of these tumors.
University of Maryland School of Medicine researchers engineered a type of CAR T-cell therapy that, in preclinical studies, selectively attacked cancer cells while sparing healthy cells, potentially reducing the likelihood of toxic side effects from this innovative cancer treatment.
Merck and Moderna have initiated a phase III randomized V940-001 clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with Keytruda (pembrolizumab) as an adjuvant treatment in patients with resected high-risk (Stage IIB-IV) melanoma.
A study led by researchers at The University of Texas MD Anderson Cancer Center demonstrates that a loss of metabolic fitness in chimeric antigen receptor (CAR) natural killer (NK) cells is a critical mechanism of resistance, with infused cells gradually losing the ability to compete with tumor cells for nutrients, leading to tumor relapse.
Investigators at the Icahn School of Medicine at Mount Sinai have designed a RNA-based strategy to activate dendritic cells—which play a key role in immune response—that eradicated tumors and prevented their recurrence in mouse models of melanoma.
The American Society of Clinical Oncology has published guidelines outlining the need to assess and manage vulnerabilities in patients aged 65 and older prior to prescribing chemotherapy, targeted therapy and/or immunotherapy.
The phase III KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating Keytruda (pembrolizumab) in combination with external beam radiotherapy (EBRT) plus concurrent chemotherapy, followed by brachytherapy (also known as concurrent chemoradiotherapy) met one of its primary endpoints of progression-free survival as treatment for newly diagnosed patients with high-risk locally advanced cervical cancer.
